Submitted by sjc313 on Thu, 08/05/2025 - 10:16
Dirk S Paul and Michael Inouye, Cardiovascular Epidemiology Unit
Department of Public Health and Primary Care
We are delighted to share our work on the proteogenomics of type 2 diabetes and related comorbidities published in Nature Communications.
The study used large-scale genomic and proteomic data from the UK Biobank and two AstraZeneca clinical trials. We identified 617 circulating proteins associated with the polygenic risk of type 2 diabetes. Of these proteins, 75% were linked to diabetic complications such as cardiovascular disease, advancing mechanistic understanding of interconnected cardiometabolic diseases.
Integrative analyses revealed putative causal proteins and therapeutic targets (e.g., FAM3D in type 2 diabetes), key causal pathways (e.g., complement cascade), and biomarkers of diabetic comorbidities (e.g., EFEMP1 and IGFBP2).
The findings from this study, which can be browsed and downloaded using an interactive web portal, will serve as a powerful resource for the research community.